FAQ/Help |
Calendar |
Search |
Today's Posts |
|
08-09-2017, 06:02 PM | #1 | ||
|
|||
Senior Member
|
What is the relationship between alpha-synuclein and Exenatide?
Given the supposed centrality of alpha-synuclein in the pathogenesis of PD, you would expect any treatment which slowed the progression of PD to involve alpha-synuclein in some way. John
__________________
Born 1955. Diagnosed PD 2005. Meds 2010-Nov 2016: Stalevo(75 mg) x 4, ropinirole xl 16 mg, rasagiline 1 mg Current meds: Stalevo(75 mg) x 5, ropinirole xl 8 mg, rasagiline 1 mg |
||
Reply With Quote |
06-14-2018, 03:00 AM | #2 | ||
|
|||
Member
|
Quite a bit has happened since we last discussed exenatide.
This recent post on the SoPD blog can help bring us all up to date. :-) What do you do with a problem like Exenatide?: What do you do with a problem like Exenatide? | The Science of Parkinson's |
||
Reply With Quote |
"Thanks for this!" says: | kiwi33 (06-14-2018) |
06-14-2018, 05:11 AM | #3 | |||
|
||||
Grand Magnate
|
Thanks jeffreyn - it is fascinating and potentially important.
As an aside, one of my colleagues has spent a long time solving the structures of venom components and then testing them for possible clinical use - it is an important research area.
__________________
Knowledge is power. |
|||
Reply With Quote |
"Thanks for this!" says: | jeffreyn (06-14-2018) |
06-15-2018, 02:18 AM | #4 | ||
|
|||
Member
|
As well as discussing exenatide, the recent SoPD post also discusses research on another GLP-1 receptor agonist called NLY01. A recent AlzForum article also provides a good overview/discussion of this NLY01 research (IMHO).
"NLY01 is on a fast track to human testing … with the goal of a Phase 2 in Parkinson’s disease in 2019." Does Taming Killer Astrocytes Spare Neurons in Parkinson’s Disease? | ALZFORUM |
||
Reply With Quote |
"Thanks for this!" says: | kiwi33 (06-15-2018) |
06-17-2018, 06:37 AM | #5 | ||
|
|||
Member
|
A Phase 2 trial of another GLP-1 receptor agonist (liraglutide) is currently recruiting PwPs (Cedars-Sinai Medical Center, Los Angeles).
Safety and Efficacy of Liraglutide in Parkinson's Disease: Safety and Efficacy of Liraglutide in Parkinson's Disease - Full Text View - ClinicalTrials.gov |
||
Reply With Quote |
09-02-2018, 06:56 AM | #6 | ||
|
|||
Member
|
Re-reading this thread recently, I noticed a question from johnt (08-09-2017), which went unanswered:
"What is the relationship between alpha-synuclein and Exenatide? Given the supposed centrality of alpha-synuclein in the pathogenesis of PD, you would expect any treatment which slowed the progression of PD to involve alpha-synuclein in some way." John probably has his answer now (from other sources), but for anyone else who may be pondering this same question, the following PNT article (about NLY01) sheds some light: Compound Similar to Diabetic Medications Slows Parkinson's Progression in Mouse Study And for anyone wanting to delve deeper, I recommend the following AlzForum article (mentioned in an earlier post): Does Taming Killer Astrocytes Spare Neurons in Parkinson’s Disease? | ALZFORUM |
||
Reply With Quote |
11-11-2019, 01:26 AM | #7 | ||
|
|||
Member
|
Simon Stott has recently done SoPD blog posts on both Exenatide and NLY01.
An exercise in expectations: Exenatide III | The Science of Parkinson's The Neuraly trial | The Science of Parkinson's |
||
Reply With Quote |
"Thanks for this!" says: | johnt (11-11-2019) |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
sept2 commentary - Is Exenatide the Next Big Thing in Parkinson’s Disease? - rehash | Parkinson's Disease | |||
june article, Exenatide and the treatment of patients with Parkinson’s disease | Parkinson's Disease | |||
hadn't seen this - Creatine LS-1 Study in Parkinson's Disease Stopped by NINDS | Parkinson's Disease | |||
Parkinson's disease stopped in animal model !! | Parkinson's Disease | |||
Supposedly Nerve Damage? | Medications & Treatments |